Study of KOS-862 (Epothilone D) in Metastatic Prostate Cancer
NCT00104130 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 53
Last updated 2008-09-17
Summary
The purpose of this trial is to study KOS-862 in men with metastatic prostate cancer who have failed a docetaxel-containing regimen.
Conditions
Interventions
- DRUG
-
KOS-862
Sponsors & Collaborators
- lead INDUSTRY
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- MALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2004-12-31
- Completion
- 2005-02-28
Countries
- United States
Study Locations
More Related Trials
-
Liposomal Doxorubicin in Treating Patients With Prostate Cancer
NCT00004014 ·Status: COMPLETED ·Phase: PHASE2
-
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
NCT06592924 ·Status: RECRUITING ·Phase: PHASE3
-
Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors
NCT04126070 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer
NCT06067841 ·Status: RECRUITING ·Phase: PHASE1
-
Crizotinib in Combination With Enzalutamide in Metastatic Castration-resistant Prostate Cancer
NCT02207504 ·Status: COMPLETED ·Phase: PHASE1
-
SHR7390 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
NCT04676607 ·Status: COMPLETED ·Phase: PHASE2
-
Estramustine, Docetaxel, and Carboplatin in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy
NCT00005627 ·Status: COMPLETED ·Phase: PHASE1
-
Phase II Metronomic Dosing, Etoposide, Cyclophosphamide, D0 Prostate Cancer
NCT00176605 ·Status: COMPLETED ·Phase: PHASE2
-
An Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate Cancer
NCT03338790 ·Status: COMPLETED ·Phase: PHASE2
-
Docetaxel and Prednisone in Treating Patients With Hormone-Refractory Metastatic Prostate Cancer
NCT00255606 ·Status: COMPLETED ·Phase: PHASE3
-
Dose-Seeking Trial of PCK3145 in Asymptomatic, Castrate Metastatic Prostate Cancer Patients.
NCT00695851 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase I/II Open-label Study of MCS110 in Patients With Prostate Cancer and Bone Metastases
NCT00757757 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Paclitaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer
NCT00003614 ·Status: COMPLETED ·Phase: PHASE2
-
BMS-247550 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy
NCT00016393 ·Status: COMPLETED ·Phase: PHASE2
-
A Trial of Immunotherapy Strategies in Metastatic Hormone-sensitive Prostate Cancer
NCT03879122 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
A Study of the Safety and Pharmacokinetics of Escalating Doses of DSTP3086S in Patients With Metastatic Castration-Resistant Prostate Cancer
NCT01283373 ·Status: COMPLETED ·Phase: PHASE1
-
Study of Dasatinib and Docetaxel in Metastatic Hormone Refractory Prostate Cancer
NCT00439270 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
R-(-)-Gossypol and Androgen Ablation Therapy in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer
NCT00666666 ·Status: COMPLETED ·Phase: PHASE2
-
Neoadjuvant Therapy With Docetaxel and Ketoconazole in Patients With High-Risk Prostate Cancer: A Pilot Study
NCT00870714 ·Status: UNKNOWN ·Phase: NA
-
Phase 2 Study of G-202 in Patients With Chemotherapy-Naïve Metastatic Castrate-Resistant Prostate Cancer
NCT01734681 ·Status: WITHDRAWN ·Phase: PHASE2
-
Combination Chemotherapy Plus Filgrastim in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy
NCT00005810 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy Study of KX2-391 for Treatment of Bone-Metastatic, Castration-Resistant Prostate Cancer
NCT01074138 ·Status: COMPLETED ·Phase: PHASE2
-
Nitrocamptothecin in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy
NCT00005820 ·Status: COMPLETED ·Phase: PHASE2
-
Weekly Paclitaxel, Low-Dose Estramustine, and Carboplatin in the Treatment of Hormone Refractory Prostate Carcinoma
NCT00193193 ·Status: COMPLETED ·Phase: PHASE2
-
EMD 525797 in Subjects With Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer
NCT01360840 ·Status: COMPLETED ·Phase: PHASE2